// App-Quantinova.ai

5041 : Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma

Researchers

Presenter

  • Rachel Cook

Principal Investigators

  • Thomas McFarland

  • Natalie Callander

  • Ronald Go

  • Stephanie Markovina

  • Shigeki Miyamoto

  • Eliot C. Williams

  • Fotios Asimakopoulos

  • Jill Kolesar

  • Michael A. Thompson

  • Kyung Mann Kim

Medical Centers

  • Department of Medical Physics, University of Wisconsin, Madison, WI

  • Biostatistics, University of Wisconsin, Madison, WI, US Virgin Islands

  • Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI

Locations

  • United States

  • US Virgin Islands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cardiotoxicity

  • Neutropenia

  • Venous thrombosis

  • Mucositis

  • Multiple Myeloma

Biomarkers

  • Fms related tyrosine kinase 1

  • Kinase Insert Domain Receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bevacizumab

  • Thalidomide

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved